ArticleFrontiers in immunology2022
Development of
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 51 citations in OpenAlex.
- The first key for the Priority Pathogens: Protective immunogens in development of vaccines and medications.Biosafety and health · 2026Review
- Immunogenic Profiling Reveals Promising RV-Identified Antigens as Vaccine Candidates AgainstInternational journal of molecular sciences · 2026Article
- Review
- DepoCatalog: mapping diversity of 129 recombinantly produced Klebsiella phage depolymerases.Nature communications · 2026Article
- Article
- A novel phage preparation capable of simultaneously inhibiting both K1 and K2 serotypes ofApplied and environmental microbiology · 2026Article
- Catalyzing Carbohydrate Cleavage: Glycosidases and Their Mechanisms.Chemical reviews · 2026Review
- Glycoconjugate Vaccines Against Nosocomial Klebsiella pneumoniae Infections.Advances in experimental medicine and biology · 2026Article
- Co-evolution of resistance and virulence inFrontiers in cellular and infection microbiology · 2026Review
- Taming Superbugs: Current Progress and Challenges in Combating ESKAPE Pathogens.Pathogens (Basel, Switzerland) · 2025Review
- Characterization and genome analysis of the Klebsiella webervirus vB_KpnS_2146-302.Archives of virology · 2025Article
- The Central Importance of Vaccines to Mitigate the Threat of Antibiotic-Resistant Bacterial Pathogens.Vaccines · 2025Review
- O-antigen polysaccharides inMicrobiology and molecular biology reviews : MMBR · 2025Review
- Antimicrobial resistance and vaccines in Enterobacteriaceae including extraintestinal pathogenic Escherichia coli and Klebsiella pneumoniae.npj antimicrobials and resistance · 2025Review
- Virulence genes, efflux pumps, and molecular typing of Klebsiella pneumoniae isolates from North Iran.AMB Express · 2025Article
- Isoferulic acid facilitates effective clearance of hypervirulent Klebsiella pneumoniae through targeting capsule.PLoS pathogens · 2025Article
- Capsular Polysaccharide as a Potential Target in Hypervirulent and Drug-ResistantInfection and drug resistance · 2025Review
- Exploring current hypervirulentFrontiers in microbiology · 2025Review
- Specificity and diversity of Klebsiella pneumoniae phage-encoded capsule depolymerases.Essays in biochemistry · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.